Showing 1 - 7 results of 7 for search 'Bijarnia, M', query time: 0.03s Refine Results
  1. 1
    Cardiac Safety of Fingolimod 0.5 mg during the First Dose Observation in 4-Month, Open-Label, Multi-Center FIRST Study in Patients with Relapsing MS

    Cardiac Safety of Fingolimod 0.5 mg during the First Dose Observation in 4-Month, Open-Label, Multi-Center FIRST Study in Patients with Relapsing MS by Comi, G, Kappos, L, Palace, J, Gottschalk, R, Bijarnia, M, Keil, A, Tomic, D, von Rosenstiel, P, Gold, R

    Published 2012
    Conference item
  2. 2
    Erratum: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study (Journal of Neurology (2014) 261 (267-276) DOI: 10.1007/s00415-013-7115-8)

    Erratum: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study (Journal of Neuro... by Gold, R, Comi, G, Palace, J, Siever, A, Gottschalk, R, Bijarnia, M, Von Rosenstiel, P, Tomic, D, Kappos, L

    Published 2014
    Journal article
  3. 3
    Erratum to: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.

    Erratum to: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. by Gold, R, Comi, G, Palace, J, Siever, A, Gottschalk, R, Bijarnia, M, von Rosenstiel, P, Tomic, D, Kappos, L

    Published 2014
    Journal article
  4. 4
    Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study

    Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study by Gold, R, Comi, G, Palace, J, Siever, A, Gottschalk, R, Bijarnia, M, Von Rosenstiel, P, Tomic, D, Kappos, L

    Published 2014
    Journal article
  5. 5
    Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.

    Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. by Gold, R, Comi, G, Palace, J, Siever, A, Gottschalk, R, Bijarnia, M, von Rosenstiel, P, Tomic, D, Kappos, L

    Published 2014
    Journal article
  6. 6
    Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients

    Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients by Gold, R, Kappos, L, Palace, J, Siever, A, Marrosu, M, Gottschalk, R, Bijarnia, M, Keil, A, Tomic, D, von Rosenstiel, P, Comi, G

    Published 2012
    Conference item
  7. 7
    Safety and tolerability of fingolimod 0.5 mg during the first 4 months of administration in patients with relapsing forms of multiple sclerosis. Results from the open-label, multicentre FIRST study

    Safety and tolerability of fingolimod 0.5 mg during the first 4 months of administration in patients with relapsing forms of multiple sclerosis. Results from the open-label, multic... by Kappos, L, Comi, G, Palace, J, Siever, A, Marrosu, M, Mehling, M, Gottschalk, R, Bijarnia, M, Keil, A, Tomic, D, von Rosenstiel, P, Gold, R

    Published 2012
    Conference item

Search Tools: